5 Key Takeaways

• 1

  CAR 422 is a mesothelin-targeting CAR T cell that shows activity in ovarian and pancreatic cancer by targeting a juxtamembrane stump of mesothelin.

• 2

  Engineered regulatory T cells, or CAlleR Tregs, reduced allergic asthma symptoms in mice by suppressing allergen-specific immune responses.

• 3

  A targeted radiopharmaceutical improved CAR T cell therapy in neuroblastoma models, enhancing tumor regression and reshaping the tumor microenvironment.

• 4

  A liver-directed lentiviral gene therapy showed durable effects in mouse models of methylmalonic acidemia, with high gene transfer efficiency.

• 5

  A gene therapy platform using engineered AAV5 capsids targets human glial cells in the brain, addressing challenges in neurological gene therapy.